Cipla Limited (CIPLA) Balance Sheet
A balance sheet shows what a company owns and owes, and shareholders' equity, at a single point in time.
Cipla Limited, together with its subsidiaries, manufactures, develops, sells, and distributes pharmaceutical products in India, the United States, South Africa, and internationally.
Total Assets Chart for Cipla Limited
Cipla Limited (CIPLA) total assets for FY2026 were INR 425.0B, a 13.7% change from FY2025. Cipla Limited's total assets grew from INR 22.2B in 2004 to INR 425.0B in 2026 (1814.1% over 22 years). Total assets compound annual growth rate: 5-year CAGR of 11.1%, 10-year CAGR of 7.2%, 20-year CAGR of 13.4%.
Total Assets (Indian Rupees)
R&D as % of Revenue
Compare with
Key Stats
- Market Cap
- ₹1.14T
- Implied Share Price
- ₹1406.10
- Enterprise Value
- ₹1.05T
- Revenue (TTM)
- ₹280.68B
- EBITDA
- ₹51.83B
- Profit Margin
- 12.01%
- Trailing P/E
- 34.21
- Forward P/E
- 24.33
- Price/Book (MRQ)
- 3.34
- Price/Sales (TTM)
- 4.05
- EV/EBITDA
- 18.40
- EV/Revenue
- 3.77
- Dividend Yield
- 0.00%
- Book Value
- ₹426.25
- Free Cash Flow (FY2026)
- ₹25.27B
- Free Cash Flow Yield
- 2.22%
Snapshot as of 27th August 2026 — not point-in-time controlled, may lag the live market by a few days.